Form 4 for CHRS Coherus Oncology, Inc.
Accepted 2022-03-01 00:00:00 ET · period of report 2022-02-25 · accession 0001567619-22-005922 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-03-01 | 2022-02-25+ | CHRS | Wahlstrom Mats | Dir | A - Grant | $4.47 | +40.0K | 40.0K | New | +$178.9K |
| D | 2022-03-01 | 2022-02-28 | CHRS | Wahlstrom Mats | Dir | M - OptEx | $0.00 | +30.0K | 0 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-25 | A | A | 10,006 | $11.64 | 10,006 | D | — | — | |
| 2 | Common | Common Stock | 2022-02-28 | A | A | 29,994 | $2.08 | 40,000 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2022-02-28 | M | A | 29,994 | $0.00 | 0 | D | $2.08 · — to 2022-12-14 | 29,994 Common Stock | (F1) The underlying shares subject to the option are fully vested and exercisable. |